Alnylam to work with PeptiDream on peptide delivery of siRNA

By The Science Advisory Board staff writers

July 30, 2021 -- Alnylam Pharmaceuticals and PeptiDream have signed a license and collaboration agreement to develop peptide-small interfering RNA (siRNA) conjugates that deliver RNA interference therapeutics to tissues outside the liver.

The companies will collaborate to optimize peptides for the targeted delivery of siRNA molecules to a range of cell types and tissues via specific interactions with receptors expressed on target cells. Under the agreement, Alnylam will select receptors for PeptiDream's peptide discovery platform. PeptiDream will select, optimize, and synthesize peptides for each receptor. Alnylam will also perform in vitro and in vivo studies to support final peptide selection.

PeptiDream will receive an upfront payment of an undisclosed amount from Alnylam, as well as R&D funding, over the course of the collaboration. PeptiDream may also receive specified development, regulatory, and commercial milestone payments. In addition, PeptiDream is eligible to receive royalties ranging from the low to mid single digits on sales of any related Alnylam products.

Rare Disease Company Coalition established
A coalition of pharmaceutical and biosciences companies has launched a new organization to educate policymakers on the challenges they face bringing therapies...
NORD announces 2021 Rare Impact Award honorees
The National Organization for Rare Disorders (NORD) announced the honorees for the 2021 Rare Impact Awards.
CHMP recommends Alnylam's RNAi therapeutic for approval
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) posted a positive opinion recommending approval for Alnylam Pharmaceutical's...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter